Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11511816 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TDP1STAT3CA2MMP1 | |
| SCHEMBL11511817 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TDP1STAT3CA2MMP1 | |
| SCHEMBL1320563 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TDP1STAT3CA2KISS1R | |
| SCHEMBL1320565 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TDP1STAT3CA2KISS1R | |
| SCHEMBL13567281 | 0.78 | STAT3 (0.46) | ALDH1A1TDP1STAT3CA2PTPN1 | |
| SCHEMBL17639989 | 0.78 | STAT3 (0.46) | ALDH1A1TDP1STAT3PTPN1PRKCA | |
| SCHEMBL16642030 | 0.77 | TDP1 (0.42) | ALDH1A1TDP1STAT3CA2MMP1 | |
| SCHEMBL8812729 | 0.77 | ALDH1A1 (0.42) | ALDH1A1TDP1STAT3CA2KISS1R | |
| SCHEMBL11018655 | 0.77 | ALDH1A1 (0.42) | ALDH1A1TDP1STAT3CA2KISS1R | |
| SCHEMBL11018652 | 0.77 | ALDH1A1 (0.42) | ALDH1A1TDP1STAT3CA2KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775098-A | Saturated alcohol and method for preparing saturated alcohol from unsaturated aldehyde ketone | 湖南长炼新材料科技股份公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119775098-A | Saturated alcohol and method for preparing saturated alcohol from unsaturated aldehyde ketone | 湖南长炼新材料科技股份公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20190241822-A1 | COMPOSITION FOR REMOVING IRON SULFIDE | KURARAY CO., LTD. (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-2930179-B1 | RUTHENIUM COMPLEX AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING RUTHENIUM-CONTAINING THIN FILM | TOSOH CORP (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-09-07 | — | — | US | disclosed |
| US-9695165-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2013155223-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| WO-2013055667-A2 | BIOCATALYSIS CELLS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012080809-A1 | PROCESS FOR PRODUCING DIBK | RHODIA POLIAMIDA E ESPECIALIDADES LTDA (BR) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011143651-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143657-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143660-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029791-B2 | Therapeutic conjugates | CD47, CD44, EPCAM | ALDH1A1 1307/4885TDP1 2678/4885STAT3 2823/4885 |
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | ALDH1A1 2337/4885TDP1 2276/4885STAT3 346/4885 |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | ALDH1A1 2544/4885TDP1 1941/4885STAT3 401/4885 |
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | ALDH1A1 2337/4885TDP1 2276/4885STAT3 346/4885 |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | ALDH1A1 1963/4885TDP1 2360/4885STAT3 343/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | ALDH1A1 4812/4885TDP1 1066/4885STAT3 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.